Gabapentin to reduce pain in women aged between 18 and 50 years with chronic pelvic pain: the GaPP2 RCT

Catherine A Hewitt,1 Katy Vincent,2 Lee J Middleton,1 Liana Romaniuk,3 Magda Koscielniak,4 Ann M Doust,4 Judy Birch,5 Heather Whalley,3 Jane P Daniels6,7 and Andrew W Horne4*
on behalf of the GaPP2 Collaborative Group

1Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK
2Nuffield Department of Women’s and Reproductive Health, University of Oxford, Oxford, UK
3Department of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
4Medical Research Council Centre for Reproductive Health, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK
5Pelvic Pain Support Network, Poole, UK
6Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK
7Nottingham Health Sciences Partners, Queen’s Medical Centre, Nottingham, UK

*Corresponding author Andrew.horne@ed.ac.uk

Declared competing interests of authors: Andrew W Horne reports grants from the National Institute for Health Research (NIHR), Medical Research Council (MRC), Chief Scientist’s Office, Wellcome Trust (London, UK), Wellbeing of Women (London, UK) and Roche (Basel, Switzerland); grants and personal fees from Ferring Pharmaceuticals (Saint-Prex, Switzerland); and personal fees from Nordic Pharma (Reading, UK), Roche Diagnostics and AbbVie (North Chicago, IL, USA), outside the submitted work. Katy Vincent reports grants and personal fees from Bayer Healthcare (Leverkusen, Germany) and personal fees from Grünenthal (Aachen, Germany), Eli Lilly and Company (Indianapolis, IN, USA) and AbbVie, outside the submitted work. Jane P Daniels is a member of the NIHR Clinical Trials Unit Standing Advisory Committee (2017 to present).

Published November 2020
DOI: 10.3310/eme07070
Scientific summary

The GaPP2 RCT
Efficacy and Mechanism Evaluation 2020; Vol. 7: No. 7
DOI: 10.3310/eme07070

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Long-standing (chronic) pelvic pain affects over 1 million women in the UK. It is the reason for 20% of gynaecological consultations and causes a 45% reduction in work productivity. The annual cost of caring for women in the UK with chronic pelvic pain has been estimated to be £154M.

The pathogenesis of the painful symptoms experienced by women with chronic pelvic pain is poorly understood. The painful symptoms are associated with specific pathological processes, such as endometriosis, but up to 55% of women with chronic pelvic pain appear to have no obvious underlying pathology.

The management of chronic pelvic pain is difficult because in the absence of underlying pathology no established gynaecological treatments are available.

Objectives of the main trial

The GaPP2 trial was designed to test the hypothesis that treatment with gabapentin has the potential to provide a safe, effective, convenient oral treatment that alleviates pain in women with chronic pelvic pain in the absence of any obvious pelvic pathology. We also wanted to test the hypothesis that treatment with gabapentin has the potential to improve physical and emotional functioning.

Objectives of the mechanistic substudy

The mechanistic component of the trial had the following objectives:

- determine the presence of central nervous system changes in women with chronic pelvic pain and no obvious underlying pathology
- determine the effect of gabapentin on central pain processing in women with chronic pelvic pain and no underlying pathology
- determine whether or not there are baseline functional magnetic resonance imaging measures that correlate with response to treatment
- determine whether or not there are clinical measures that correlate with response to treatment.

Design

This was a randomised, double-blind, placebo-controlled, multicentre trial with a mechanistic substudy to explore the mechanism of action of gabapentin.

Methods

Setting

The trial was conducted in 39 sites in NHS hospital settings across the UK, recruiting between 2015 and 2019. The mechanistic substudy was conducted only at the Edinburgh Imaging Facility at the University of Edinburgh.
Participants
For the main trial, informed consent was sought from women (aged between 18 and 50 years) with chronic pelvic pain and no obvious pelvic pathology at laparoscopy. For the mechanistic substudy, Edinburgh participants who consented to the main trial were approached to undergo a functional magnetic resonance imaging scan of the brain.

Interventions
Each participant received either gabapentin capsules at a dose of 300 mg three times per day (increased to a maximum dose of 2700 mg) or placebo capsules. These were commenced at randomisation and continued for a total of 16 weeks (4-week dose escalation followed by 12 weeks on the optimal dose). Optimal dosing was determined by the participants, who were instructed to increase their dose until they perceived adequate pain relief or intolerance to perceived side effects. Neither the clinician nor the participant knew which group they were allocated to throughout the study.

Screening and randomisation
Participants were asked to return numerical rating pain scores weekly for 4 weeks on both the average and the worst scales (scores range from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable). If at least three of the four pain scores were returned on both scales and at least two of the worst pain scores were ≥ 4, then the woman was considered fully eligible for the trial and was invited to attend a randomisation visit. Randomisation was performed online via a secure internet facility. Women were unblinded at the end of the treatment phase after all data were collected.

Outcome measures

Primary
Dual measures of worst and average pelvic pain scores assessed weekly by a numerical rating scale at baseline and then during the final 4 weeks of treatment (weeks 13–16 post randomisation).

Secondary
- Numerical rating score of pain: to include an examination of the proportion of women who have a 30% or 50% reduction in average and worst pain scores from baseline to the end of treatment (pain scores ranging from 0, no pain, to 10, worst pain imaginable).
- Short Form-12 quality of life: the Short Form Health Survey provides summary information on physical and mental health status.
- Brief Pain Inventory: a comprehensive instrument for pain assessment.
- Brief Fatigue Inventory: to measure the severity of fatigue in adults.
- General Health Questionnaire (short): to identify psychological distress.
- Work and Productivity Activity Impairment: a valid questionnaire for assessing impairments in paid work and activities.
- Pain Catastrophizing Scale: one of the most widely used instruments for measuring catastrophic thinking related to pain.
- Sexual Activity Questionnaire: a valid, reliable and acceptable measure for describing the sexual functioning of women in terms of pleasure and discomfort.
- PainDETECT™: a new screening questionnaire to identify neuropathic components in patients.
- Pelvic Pain and Urinary/Frequency Patient Symptom Scale (baseline only): a questionnaire that is predictive of treatment success.
- Number of attendances to health-care professionals for chronic pelvic pain.
- Use of concomitant medications was recorded to identify any reductions in analgesic use.
**Mechanistic substudy**

Brain activity (measured by functional magnetic resonance imaging) at rest and evoked in response to punctate stimuli.

**Results**

**Main trial**

A total of 1348 participants were approached for participation, and 414 were consented to the initial screening phase. Of these women, 306 were randomised, 153 allocated to gabapentin and 153 allocated to placebo. Ten women withdrew from GaPP2 and one woman died. In addition, primary outcome data were unavailable in 62 and 60 women for the average and worst pain scores, respectively. Sensitivity analyses using a multiple imputation approach were performed to assess the effect of missing responses.

The baseline data (age, body mass index and maternal ethnicity) of the participants were comparable in the two groups of the trial. In weeks 13–16, the mean worst pain score was 7.1 (standard deviation 2.6) in the gabapentin group and 7.4 (standard deviation 2.2) in the placebo group (adjusted mean difference −0.20, 97.5% confidence interval −0.81 to 0.42; \( p = 0.47 \)). The mean average pain score was 4.3 (standard deviation 2.3) in the gabapentin group and 4.5 (standard deviation 2.2) in the placebo group (adjusted mean difference −0.18, 97.5% confidence interval −0.71 to 0.35; \( p = 0.45 \)). No significant between-group differences were observed for any secondary outcome. A higher proportion of women experienced a serious adverse event in the gabapentin group than in the placebo group (10/153 vs. 3/153; \( p = 0.04 \)). Dizziness, drowsiness and visual disturbances were more common in the gabapentin group.

**Mechanistic substudy**

A total of 83 women were consented in Edinburgh for the main trial. Of these, 45 consented to take part in the mechanistic study and had a baseline functional magnetic resonance imaging brain scan; 25 returned for a follow-up scan between weeks 12 and 16 of treatment. Twelve women were in the placebo group and 13 were in the gabapentin group. Whole-brain and a priori defined region of interest analyses were performed. Group mean activation included regions known to be important in the processing of pain. Compared with placebo, gabapentin reduced evoked activity in the anterior cingulate cortex and the cuneus. In the gabapentin group, changes in activity in the anterior cingulate cortex tracked with clinically meaningful improvements (Brief Pain Inventory pain interference scores); however, this was not the case for the cuneus. Baseline evoked activity in the anterior cingulate cortex was also a predictor of response, with those with the greatest activity having a greater improvement in the physical component of the Short Form-12 and reduction in their PainDETECT scores.

**Conclusions**

Gabapentin did not reduce pain scores and did not improve other outcomes compared with placebo over the course of 16 weeks. Serious adverse effects were significantly higher in the gabapentin group than in the placebo group. In the mechanistic study, gabapentin exerted a clinically relevant effect on the anterior cingulate cortex.

Women with chronic pelvic pain and no obvious pelvic pathology should be advised that gabapentin may not alleviate their pain and may give them unpleasant side effects. No further research is required. Questions that remain unaddressed relate to the use of other pharmacological interventions (monotherapy vs. combination therapy), physiotherapy and cognitive–behavioural therapy for treating women with chronic pelvic pain.
Trial registration

This trial is registered as ISRCTN77451762 and EudraCT 2014-005035-13.

Funding

This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy and Mechanism Evaluation; Vol. 7, No. 7. See the NIHR Journals Library website for further project information.
Criteria for inclusion in the Efficacy and Mechanism Evaluation Journal

Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme support translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

This report

The research reported in this issue of the journal was funded by the EME programme as project number 13/52/04. The contractual start date was in March 2015. The final report began editorial review in February 2020 and was accepted for publication in August 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2020. This work was produced by Hewitt et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of *Efficacy and Mechanism Evaluation* and NIHR Journals Library

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

**Professor John Powell**  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May**  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck**  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson**  Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont**  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** journals.library@nihr.ac.uk